Gil Omenn is an expert in genetics, proteomics, bioinformatics, and precision medicine. He is Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health, and Director of the University-wide Center for Computational Medicine & Bioinformatics at the University of Michigan. He is a former Howard Hughes Medical Institute Investigator, a longtime NCI-funded PI, a physician long involved in Genetic Counseling at the University of Washington and University of Michigan, and the first CEO of the University of Michigan Health System. His current work in proteogenomics is focused on alternative splice variants as a new class of potential protein cancer biomarkers. He is the elected Chair of the global Human Proteome Project. More broadly, he serves on the elected Council of the National Academy of Medicine; was president and board chair of the American Association for the Advancement of Science (AAAS); chaired the Presidential/Congressional Commission on Risk Assessment and Risk Management during 1994-1997 and the Institute of Medicine 2012 report on “Evolution of Translational Omics: Lessons Learned and Path Forward”; co-chaired the i2b2 tranSMART Foundation; and has served on the boards of Amgen Inc, Rohm & Haas Company, Esperion Therapeutics, Galectin Therapeutics, and Oncofusion. He has been involved in the Personalized Medicine World Conferences for several years.